Your browser doesn't support javascript.
loading
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Feagan, B G; Sandborn, W J; Baker, J P; Cominelli, F; Sutherland, L R; Elson, C O; Salzberg, B A; Archambault, A; Bernstein, C N; Lichtenstein, G R; Heath, P K; Cameron, S; Hanauer, S B.
Affiliation
  • Feagan BG; The John P Robarts Research Institute, University of Western Ontario, London, ON, Canada. bfeagan@robarts.ca
Aliment Pharmacol Ther ; 21(4): 373-84, 2005 Feb 15.
Article in En | MEDLINE | ID: mdl-15709987
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Agents / Crohn Disease / Anti-Inflammatory Agents, Non-Steroidal / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2005 Type: Article Affiliation country: Canada
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Agents / Crohn Disease / Anti-Inflammatory Agents, Non-Steroidal / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2005 Type: Article Affiliation country: Canada